keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#1
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
https://www.readbyqxmd.com/read/29143681/economic-evaluation-of-hcv-testing-approaches-in-low-and-middle-income-countries
#2
REVIEW
Jake R Morgan, Maria Servidone, Philippa Easterbrook, Benjamin P Linas
BACKGROUND: Hepatitis C virus (HCV) infection represents a major public health burden with diverse epidemics worldwide, but at present, only a minority of infected persons have been tested and are aware of their diagnosis. The advent of highly effective direct acting antiviral (DAA) therapy, which is becoming available at increasingly lower costs in low and middle income countries (LMICs), represents a major opportunity to expand access to testing and treatment. However, there is uncertainty as to the optimal testing approaches and who to prioritize for testing...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143626/methodological-challenges-in-appraising-evidence-on-diagnostic-testing-for-who-guidelines-on-hepatitis-b-and-hepatitis-c-virus-infection
#3
Roger Chou, Philippa Easterbrook, Margaret Hellard
Linking persons with hepatitis B (HBV) and hepatitis C (HCV) infection with appropriate prevention and treatment requires that they first be diagnosed. The World Health Organization (WHO) has developed its first guidelines on testing for chronic HBV and HCV infection, using a framework based on methods from the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working Group for the formulation of recommendations, including determining the strength of recommendations and quality of evidence...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143620/optimising-diagnosis-of-viraemic-hepatitis-c-infection-the-development-of-a-target-product-profile
#4
Elena Ivanova Reipold, Philippa Easterbrook, Alessandra Trianni, Nivedha Panneer, Douglas Krakower, Stefano Ongarello, Teri Roberts, Veronica Miller, Claudia Denkinger
BACKGROUND: The current low access to virological testing to confirm chronic viraemic HCV infection in low- and middle-income countries (LMIC) is limiting the rollout of hepatitis C (HCV) care. Existing tests are complex, costly and require sophisticated laboratory infrastructure. Diagnostic manufacturers need guidance on the optimal characteristics a virological test needs to have to ensure the greatest impact on HCV diagnosis and treatment in LMIC. Our objective was to develop a target product profile (TPP) for diagnosis of HCV viraemia using a global stakeholder consensus-based approach...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143611/one-or-two-serological-assay-testing-strategy-for-diagnosis-of-hbv-and-hcv-infection-the-use-of-predictive-modelling
#5
John V Parry, Philippa Easterbrook, Anita R Sands
BACKGROUND: Initial serological testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is conducted using either rapid diagnostic tests (RDT) or laboratory-based enzyme immunoassays (EIA)s for detection of hepatitis B surface antigen (HBsAg) or antibodies to HCV (anti-HCV), typically on serum or plasma specimens and, for certain RDTs, capillary whole blood. WHO recommends the use of standardized testing strategies - defined as a sequence of one or more assays to maximize testing accuracy while simplifying the testing process and ideally minimizing cost...
November 1, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29135608/the-epidemiology-of-vertebral-osteomyelitis-in-the-united-states-from-1998-to-2013
#6
Kimona Issa, Bassel G Diebo, Michael Faloon, Qais Naziri, Sina Pourtaheri, Carl B Paulino, Arash Emami
STUDY DESIGN: This is a epidemiological database analysis. OBJECTIVES: The objectives of this article are to assess the following characteristics of vertebral osteomyelitis (VO): (1) incidence and patient demographics, (2) mortality rate, (3) length-of-stay (LOS), and (4) admission costs. SUMMARY OF BACKGROUND: VO is a serious disease with potentially devastating clinical consequences. At present, there is limited data on the epidemiology of VO in the United States as previous reports are based on older studies with small sample sizes...
November 10, 2017: Clinical Spine Surgery
https://www.readbyqxmd.com/read/29134150/hcv-core-antigen-is-an-alternative-marker-to-hcv-rna-for-evaluating-active-hcv-infection-implications-for-improved-diagnostic-option-in-an-era-of-affordable-daas
#7
Rujipat Wasitthankasem, Preeyaporn Vichaiwattana, Chompoonut Auphimai, Nipaporn Siripon, Sirapa Klinfueng, Pisit Tangkijvanich, Sompong Vongpunsawad, Yong Poovorawan
The core antigen of the hepatitis C virus (HCV Ag) presents an alternative marker to HCV RNA when screening patients for HCV viremia. This study sought to evaluate the utility of HCV Ag as a marker to assess active HCV infection in individuals residing in an HCV-endemic area. From 298 HCV-seropositive individuals evaluated for the presence of anti-HCV antibody, HCV Ag and HCV RNA, anti-HCV antibody was detected in 252 individuals (signal-to-cutoff ratios ≥5), HCV RNA was detected in 222 individuals (88%), and HCV Ag was reactive (≥3 fmol/L) in 220 individuals (87%)...
2017: PeerJ
https://www.readbyqxmd.com/read/29133244/real-world-effectiveness-of-8-weeks-treatment-with-ledipasvir-sofosbuvir-in-chronic-hepatitis-c
#8
Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Anita Pathil, Klaus Boeker, Tim Zimmermann, Gerlinde Teuber, Heike-Pfeiffer Vornkahl, Karl-Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem
BACKGROUND AND AIMS: Ledipasvir/Sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study 8 weeks of LDV/SOF was non-inferior to 12 weeks in previously untreated genotype 1 (GT1) patients without cirrhosis. According to the summary of product characteristics (SmPC), 8 weeks treatment may be considered in naïve non-cirrhotic GT1-patients. However, there are only limited data on the effectiveness of 8 week regimen of LDV/SOF under real-world conditions available...
November 10, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29121533/novel-treatments-for-chronic-hepatitis-c-closing-the-remaining-gaps
#9
REVIEW
Naim Alkhouri, Eric Lawitz, Fred Poordad
Direct acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection with cure rates >90% for the majority of patients and excellent safety profile. However, there remain certain unmet needs in treating HCV including treatment for patients that failed a prior DAA regimen and for those with advanced chronic kidney disease. In addition, shortening the duration of DAA regimens has the potential to increase compliance and decrease the cost of care. New regimens that were approved by the FDA in 2017 address these unmet needs and will be discussed in this concise review...
November 6, 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29109499/cost-effective-but-unaffordable-and-unequal-hepatitis-c-treatment-in-the-us
#10
Xibei Liu, Jay J Shen, Jeong Lim Lee, Ji Won Yoo
No abstract text is available yet for this article.
November 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29106926/increasing-prevalence-of-hepatitis-c-among-hospitalized-children-is-associated-with-an-increase-in-substance-abuse
#11
A Sidney Barritt, Brian Lee, Thomas Runge, Monica Schmidt, Ravi Jhaveri
OBJECTIVE: To evaluate the impact of substance abuse on pediatric hepatitis C virus (HCV) prevalence, we examined geographic and demographic data on inpatient hospitalizations in children with HCV. STUDY DESIGN: We examined hospitalizations in children using the Kids' Inpatient Database, a part of the Healthcare Cost and Utilization Project. We identified cases using the International Classification of Diseases, 9th edition, codes for HCV infection during 2006, 2009, and 2012...
October 26, 2017: Journal of Pediatrics
https://www.readbyqxmd.com/read/29096647/hepatitis-c-infection-related-services-and-barriers-to-hcv-treatment-among-drug-users-in-methadone-maintenance-treatment-mmt-clinics-in-shanghai-china
#12
Zhi-Bin Li, Lei Zhang, Jun Wang, Le-Ping Huang, Zhi-Rong Zhou, Yi-Ning Cao, Min Zhao, Jiang Du
BACKGROUND: The purpose of this study was to document the prevalence of hepatitis C among MMT patients, hepatitis C virus (HCV) knowledge of patients and MMT staff members, and the barriers preventing them from receiving or delivering HCV-related services in MMT clinics of China. METHODS: Data were collected from 240 MMT patients and 58 staff members in Shanghai MMT clinics. Structured questionnaires (HCV Knowledge Scale and Alcohol Use Disorders Identification Test) and several self-developed questionnaires were used to assess (1) patient and staff HCV knowledge, (2) attitudes toward HCV-related services in MMT clinics, and (3) what type of HCV-related services the staff members have provided in their routine work...
November 2, 2017: Harm Reduction Journal
https://www.readbyqxmd.com/read/29089195/superior-immunogenicity-of-hcv-envelope-glycoproteins-when-adjuvanted-with-cyclic-di-amp-a-sting-activator-or-archaeosomes
#13
A Landi, J Law, D Hockman, M Logan, K Crawford, C Chen, J Kundu, T Ebensen, C A Guzman, L Deschatelets, L Krishnan, D L J Tyrrell, M Houghton
Three decades after the discovery, hepatitis C virus (HCV) is still the leading cause of liver transplantation and poses a major threat to global health. In spite of recent advances in the development of direct acting antivirals, there is still a need for a prophylactic vaccine to limit the virus spread and protect at-risk populations, especially in developing countries, where the cost of the new treatments may severely limit access. The use of recombinant HCV glycoproteins E1E2 (rE1E2) in combination with the MF59, an oil-in-water emulsion-based adjuvant, has previously been shown to reduce the rate of chronicity in chimpanzees and to induce production of cross-neutralizing antibodies and cellular immune responses in human volunteers...
October 28, 2017: Vaccine
https://www.readbyqxmd.com/read/29088981/hepatitis-c-point-of-care-diagnostics-in-search-of-a-single-visit-diagnosis
#14
Jason Grebely, Tanya L Applegate, Philip Cunningham, Jordan J Feld
The availability of simple, tolerable, therapies for hepatitis C virus (HCV) infection with responses >95% is one of the greatest medical advances in decades, offering an opportunity to reverse the rising burden due to HCV and strive towards HCV elimination. A key challenge moving forward will be to ensure that those who are undiagnosed are made aware of their infection, receive HCV therapy and achieve viral cure. The availability of point-of-care tests for HCV infection has the potential to simplify testing algorithms, increase diagnoses, and facilitate linkage to treatment...
November 1, 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/29081211/estimation-of-direct-medical-costs-related-to-chronic-hepatitis-c-a-rationale-for-early-antiviral-therapy
#15
EDITORIAL
Do Young Kim
No abstract text is available yet for this article.
November 15, 2017: Gut and Liver
https://www.readbyqxmd.com/read/29080433/hepatitis-c-virus-hcv-rna-screening-and-sequencing-using-dry-plasma-spots
#16
Anna Maria Geretti, Simon King, Kwabena Adjei-Asante, Lambert Tetteh Appiah, Dorcas Ohui Owusu, Fred Stephen Sarfo, David Chadwick, Richard Odame Phillips, Apostolos Beloukas
BACKGROUND: HCV RNA screening of large sample repositories provides data on HCV epidemic patterns that may help guide control policies. In resource-limited settings, shipment of frozen samples to molecular laboratory facilities and testing of individual samples may be prohibitively expensive. OBJECTIVE: Our aim was to detect and sequence HCV RNA in a large HIV-positive cohort from Kumasi, Ghana, using pooled and individual dried plasma spots (DPS) produced from samples stored at -80°C...
October 23, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/29074450/cost-effectiveness-of-access-expansion-to-treatment-of-hepatitis-c-virus-infection-through-primary-care-providers
#17
Thilo Rattay, Ian P Dumont, Hauke S Heinzow, David W Hutton
BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major burden on individuals and health care systems. The Extension for Community Healthcare Outcomes (Project ECHO) enables primary care providers to deliver best-practice care for complex conditions to underserved populations. The US Congress passed the ECHO Act in late 2016, requiring the Department of Health and Human Services to investigate the model. We performed a cost-effectiveness analysis to assess diagnosis and treatment of HCV infection in a primary care patient panel with and without the implementation of Project ECHO...
October 23, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29074218/avasimibe-a-novel-hepatitis-c-virus-inhibitor-that-targets-the-assembly-of-infectious-viral-particles
#18
Longbo Hu, Jinqian Li, Hua Cai, Wenxia Yao, Jing Xiao, Yi-Ping Li, Xiu Qiu, Huimin Xia, Tao Peng
Direct-acting antivirals (DAAs), which target hepatitis C virus (HCV) proteins, have exhibited impressive efficacy in the management of chronic hepatitis C. However, the concerns regarding high costs, drug resistance mutations and subsequent unexpected side effects still call for the development of host-targeting agents (HTAs) that target host factors involved in the viral life cycle and exhibit pan-genotypic antiviral activity. Given the close relationship between lipid metabolism and the HCV life cycle, we investigated the anti-HCV activity of a series of lipid-lowering drugs that have been approved by government administrations or proven safety in clinical trials...
October 23, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29073993/cost-effectiveness-analysis-of-new-hcv-treatments-in-egyptian-cirrhotic-and-non-cirrhotic-patients-a-societal-perspective
#19
Gihan Hamdy Elsisi, Asmaa Aburawash, Emam Waked
OBJECTIVES: To evaluate the cost-effectiveness of sofosbuvir (SOF) + ribavirin (RBV), SOF + daclatasvir (DCV), and SOF + ledipasvir (LDV) + RBV compared with SOF + pegylated interferon alfa (pegIFN) + RBV in the treatment of patients infected with hepatitis C virus in Egypt. METHODS: Two Markov models were developed on the basis of the Egyptian clinical data and practice and were derived from published sources. The clinical parameters were derived from two sources: the Egypt multicenter national treatment program and previously published randomized clinical trials...
September 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/29066922/epidemiology-patient-profile-and-health-care-resource-use-for-hepatitis-c-in-italy
#20
Diego Sangiorgi, Valentina Perrone, Stefano Buda, Lucio Boglione, Giuseppe Cariti, Cinira Lefevre, Carmela Nappi, Luca Degli Esposti
OBJECTIVE: The objectives of this study were to estimate the prevalence of Hepatitis C among six Italian Local Health Units (LHUs), to describe patient and antiviral drug characteristics, and to estimate the health care consumption rates and related costs for the management of patients affected by hepatitis C virus (HCV) infection by using data from routine clinical practice. METHODS: We conducted a retrospective study using administrative databases of six Italian LHUs...
2017: ClinicoEconomics and Outcomes Research: CEOR
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"